
[Federal Register: October 2, 2009 (Volume 74, Number 190)]
[Notices]               
[Page 50980]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02oc09-52]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0664]

 
Oncologic Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Oncologic Drugs Advisory Committee 
scheduled for October 6, 2009, is cancelled. This meeting was announced 
in the Federal Register of August 25, 2009 (74 FR 42907). The October 
6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss 
ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade 
name FERRIPROX (deferiprone) film-coated tablets. This meeting has been 
cancelled to allow time for FDA to review and resolve several 
outstanding issues. The agency intends to continue evaluating NDA 021-
825 and, as needed, may schedule an advisory committee meeting in the 
future.

FOR FURTHER INFORMATION CONTACT: Nicole Vesely, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301-827-6793, FAX: 301-827-6776, e-mail: 
nicole.vesely@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area), code 
3014512542. Please call the Information Line for up-to-date information 
on this meeting.

    Dated: September 28, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-23764 Filed 10-1-09; 8:45 am]

BILLING CODE 4160-01-S
